Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.
2.

A Phase III open-label trial to evaluate efficacy and safety of CPI-613 plus modified FOLFIRINOX (mFFX) versus FOLFIRINOX (FFX) in patients with metastatic adenocarcinoma of the pancreas.

Philip PA, Buyse ME, Alistar AT, Rocha Lima CM, Luther S, Pardee TS, Van Cutsem E.

Future Oncol. 2019 Oct;15(28):3189-3196. doi: 10.2217/fon-2019-0209. Epub 2019 Sep 12.

PMID:
31512497
3.

Inflammatory biomarkers, geriatric assessment, and treatment outcomes in acute myeloid leukemia.

Loh KP, Tooze JA, Nicklas BJ, Kritchevsky SB, Williamson JD, Ellis LR, Powell BL, Pardee TS, Goyal NG, Klepin HD.

J Geriatr Oncol. 2019 Apr 5. pii: S1879-4068(19)30041-4. doi: 10.1016/j.jgo.2019.03.014. [Epub ahead of print]

PMID:
30962090
4.

Systematic Dissection of the Metabolic-Apoptotic Interface in AML Reveals Heme Biosynthesis to Be a Regulator of Drug Sensitivity.

Lin KH, Xie A, Rutter JC, Ahn YR, Lloyd-Cowden JM, Nichols AG, Soderquist RS, Koves TR, Muoio DM, MacIver NJ, Lamba JK, Pardee TS, McCall CM, Rizzieri DA, Wood KC.

Cell Metab. 2019 May 7;29(5):1217-1231.e7. doi: 10.1016/j.cmet.2019.01.011. Epub 2019 Feb 14.

PMID:
30773463
5.

Association between glycemic control, age, and outcomes among intensively treated patients with acute myeloid leukemia.

Kuhlman P, Isom S, Pardee TS, Burns C, Tawfik B, Lamar ZS, Powell BL, Klepin HD.

Support Care Cancer. 2019 Aug;27(8):2877-2884. doi: 10.1007/s00520-018-4582-6. Epub 2018 Dec 15.

PMID:
30554278
6.

Mitochondria in cancer metabolism, an organelle whose time has come?

Anderson RG, Ghiraldeli LP, Pardee TS.

Biochim Biophys Acta Rev Cancer. 2018 Aug;1870(1):96-102. doi: 10.1016/j.bbcan.2018.05.005. Epub 2018 May 26. Review.

7.

A Phase I Study of CPI-613 in Combination with High-Dose Cytarabine and Mitoxantrone for Relapsed or Refractory Acute Myeloid Leukemia.

Pardee TS, Anderson RG, Pladna KM, Isom S, Ghiraldeli LP, Miller LD, Chou JW, Jin G, Zhang W, Ellis LR, Berenzon D, Howard DS, Hurd DD, Manuel M, Dralle S, Lyerly S, Powell BL.

Clin Cancer Res. 2018 May 1;24(9):2060-2073. doi: 10.1158/1078-0432.CCR-17-2282. Epub 2018 Feb 6.

8.

Outcomes and changes in code status of patients with acute myeloid leukemia undergoing induction chemotherapy who were transferred to the intensive care unit.

Ahmed T, Koch AL, Isom S, Klepin HD, Bishop JM, Ellis LR, Berenzon D, Howard D, Lyerly S, Powell BL, Pardee TS.

Leuk Res. 2017 Nov;62:51-55. doi: 10.1016/j.leukres.2017.09.017. Epub 2017 Sep 27.

9.

The novel phospholipid mimetic KPC34 is highly active against preclinical models of Philadelphia chromosome positive acute lymphoblastic leukemia.

Alexander PM, Caudell DL, Kucera GL, Pladna KM, Pardee TS.

PLoS One. 2017 Jun 23;12(6):e0179798. doi: 10.1371/journal.pone.0179798. eCollection 2017.

10.

Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial.

Alistar A, Morris BB, Desnoyer R, Klepin HD, Hosseinzadeh K, Clark C, Cameron A, Leyendecker J, D'Agostino R Jr, Topaloglu U, Boteju LW, Boteju AR, Shorr R, Zachar Z, Bingham PM, Ahmed T, Crane S, Shah R, Migliano JJ, Pardee TS, Miller L, Hawkins G, Jin G, Zhang W, Pasche B.

Lancet Oncol. 2017 Jun;18(6):770-778. doi: 10.1016/S1470-2045(17)30314-5. Epub 2017 May 8.

11.

Effect of Intensive Chemotherapy on Physical, Cognitive, and Emotional Health of Older Adults with Acute Myeloid Leukemia.

Klepin HD, Tooze JA, Pardee TS, Ellis LR, Berenzon D, Mihalko SL, Danhauer SC, Rao AV, Wildes TM, Williamson JD, Powell BL, Kritchevsky SB.

J Am Geriatr Soc. 2016 Oct;64(10):1988-1995. doi: 10.1111/jgs.14301. Epub 2016 Sep 14.

12.

A Phase II Clinical Trial of CPI-613 in Patients with Relapsed or Refractory Small Cell Lung Carcinoma.

Lycan TW, Pardee TS, Petty WJ, Bonomi M, Alistar A, Lamar ZS, Isom S, Chan MD, Miller AA, Ruiz J.

PLoS One. 2016 Oct 12;11(10):e0164244. doi: 10.1371/journal.pone.0164244. eCollection 2016.

13.

The applications of the novel polymeric fluoropyrimidine F10 in cancer treatment: current evidence.

Gmeiner WH, Debinski W, Milligan C, Caudell D, Pardee TS.

Future Oncol. 2016 Sep;12(17):2009-20. doi: 10.2217/fon-2016-0091. Epub 2016 Jun 9. Review.

14.

Improving nucleoside analogs via lipid conjugation: Is fatter any better?

Alexander P, Kucera G, Pardee TS.

Crit Rev Oncol Hematol. 2016 Apr;100:46-56. doi: 10.1016/j.critrevonc.2016.01.015. Epub 2016 Jan 21. Review.

15.

Comorbidity, age, and mortality among adults treated intensively for acute myeloid leukemia (AML).

Tawfik B, Pardee TS, Isom S, Sliesoraitis S, Winter A, Lawrence J, Powell BL, Klepin HD.

J Geriatr Oncol. 2016 Jan;7(1):24-31. doi: 10.1016/j.jgo.2015.10.182. Epub 2015 Oct 30.

16.

High dose cytarabine, mitoxantrone and l-asparaginase (HAMA) salvage for relapsed or refractory acute myeloid leukemia (AML) in the elderly.

Ahmed T, Holwerda S, Klepin HD, Isom S, Ellis LR, Lyerly S, Manuel M, Dralle S, Berenzon D, Powell BL, Pardee TS.

Leuk Res. 2015 Sep;39(9):945-9. doi: 10.1016/j.leukres.2015.05.010. Epub 2015 Jun 1.

17.

Clinicopathological analysis of near-tetraploidy/tetraploidy acute myeloid leukaemia.

Pang CS, Pettenati MJ, Pardee TS.

J Clin Pathol. 2015 Mar;68(3):236-40. doi: 10.1136/jclinpath-2014-202697. Epub 2015 Jan 6.

18.

Thymineless death in F10-treated AML cells occurs via lipid raft depletion and Fas/FasL co-localization in the plasma membrane with activation of the extrinsic apoptotic pathway.

Gmeiner WH, Jennings-Gee J, Stuart CH, Pardee TS.

Leuk Res. 2015 Feb;39(2):229-35. doi: 10.1016/j.leukres.2014.11.006. Epub 2014 Nov 29.

19.

The efficacy of the ribonucleotide reductase inhibitor Didox in preclinical models of AML.

Cook GJ, Caudell DL, Elford HL, Pardee TS.

PLoS One. 2014 Nov 17;9(11):e112619. doi: 10.1371/journal.pone.0112619. eCollection 2014.

20.

A phase I study of the first-in-class antimitochondrial metabolism agent, CPI-613, in patients with advanced hematologic malignancies.

Pardee TS, Lee K, Luddy J, Maturo C, Rodriguez R, Isom S, Miller LD, Stadelman KM, Levitan D, Hurd D, Ellis LR, Harrelson R, Manuel M, Dralle S, Lyerly S, Powell BL.

Clin Cancer Res. 2014 Oct 15;20(20):5255-64. doi: 10.1158/1078-0432.CCR-14-1019. Epub 2014 Aug 27.

21.

The prognostic importance of polypharmacy in older adults treated for acute myelogenous leukemia (AML).

Elliot K, Tooze JA, Geller R, Powell BL, Pardee TS, Ritchie E, Kennedy L, Callahan KE, Klepin HD.

Leuk Res. 2014 Oct;38(10):1184-90. doi: 10.1016/j.leukres.2014.06.018. Epub 2014 Jul 7.

22.

Acute myeloid leukemia and myelodysplastic syndromes in older adults.

Klepin HD, Rao AV, Pardee TS.

J Clin Oncol. 2014 Aug 20;32(24):2541-52. Review.

23.

The poison oligonucleotide F10 is highly effective against acute lymphoblastic leukemia while sparing normal hematopoietic cells.

Pardee TS, Stadelman K, Jennings-Gee J, Caudell DL, Gmeiner WH.

Oncotarget. 2014 Jun 30;5(12):4170-9.

24.

Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia.

Klepin HD, Geiger AM, Tooze JA, Kritchevsky SB, Williamson JD, Pardee TS, Ellis LR, Powell BL.

Blood. 2013 May 23;121(21):4287-94. doi: 10.1182/blood-2012-12-471680. Epub 2013 Apr 2.

25.

Non-homologous end joining mediated DNA repair is impaired in the NUP98-HOXD13 mouse model for myelodysplastic syndrome.

Puthiyaveetil AG, Reilly CM, Pardee TS, Caudell DL.

Leuk Res. 2013 Jan;37(1):112-6. doi: 10.1016/j.leukres.2012.10.012. Epub 2012 Nov 4.

26.

Replication-dependent irreversible topoisomerase 1 poisoning is responsible for FdUMP[10] anti-leukemic activity.

Jennings-Gee J, Pardee TS, Gmeiner WH.

Exp Hematol. 2013 Feb;41(2):180-188.e4. doi: 10.1016/j.exphem.2012.10.007. Epub 2012 Oct 17.

27.

Animal models of leukemia: any closer to the real thing?

Cook GJ, Pardee TS.

Cancer Metastasis Rev. 2013 Jun;32(1-2):63-76. doi: 10.1007/s10555-012-9405-5. Review.

28.

Overexpression of MN1 confers resistance to chemotherapy, accelerates leukemia onset, and suppresses p53 and Bim induction.

Pardee TS.

PLoS One. 2012;7(8):e43185. doi: 10.1371/journal.pone.0043185. Epub 2012 Aug 14.

29.

Unique dual targeting of thymidylate synthase and topoisomerase1 by FdUMP[10] results in high efficacy against AML and low toxicity.

Pardee TS, Gomes E, Jennings-Gee J, Caudell D, Gmeiner WH.

Blood. 2012 Apr 12;119(15):3561-70. doi: 10.1182/blood-2011-06-362442. Epub 2012 Feb 23.

30.

The feasibility of inpatient geriatric assessment for older adults receiving induction chemotherapy for acute myelogenous leukemia.

Klepin HD, Geiger AM, Tooze JA, Kritchevsky SB, Williamson JD, Ellis LR, Levitan D, Pardee TS, Isom S, Powell BL.

J Am Geriatr Soc. 2011 Oct;59(10):1837-46. doi: 10.1111/j.1532-5415.2011.03614.x. Epub 2011 Sep 13.

31.

Flt3-ITD alters chemotherapy response in vitro and in vivo in a p53-dependent manner.

Pardee TS, Zuber J, Lowe SW.

Exp Hematol. 2011 Apr;39(4):473-485.e4. doi: 10.1016/j.exphem.2011.01.009. Epub 2011 Feb 1.

32.

Mouse models of human AML accurately predict chemotherapy response.

Zuber J, Radtke I, Pardee TS, Zhao Z, Rappaport AR, Luo W, McCurrach ME, Yang MM, Dolan ME, Kogan SC, Downing JR, Lowe SW.

Genes Dev. 2009 Apr 1;23(7):877-89. doi: 10.1101/gad.1771409.

36.

Supplemental Content

Loading ...
Support Center